Founding General Partner at Norrsken VC
Check size: Norrsken VC currently states €1M–€10M early-stage and growth tickets. This is the firm's range, not Tove's personal promise. Confirm initial ticket, follow-on reserves, ownership and stage with the team.
Tove backs ambitious European technology companies whose commercial growth directly improves outcomes for people or planet. Her Bain private-equity background and early impact roles add rigorous market and diligence discipline. Current health-AI work highlights companies that combine deep sector expertise, proprietary data and measurable time or cost improvements in critical systems such as clinical trials.
Explain the system failure, affected users, founder's domain insight, product and technical advantage, validation, customer adoption, time or cost improvement, business model, impact KPI and counterfactual, data and regulatory plan, expansion, round and fit with the current €1M–€10M range. For health AI, address clinical evidence and workflow integration.
Bold founders, deep domain expertise, an urgent system problem, technology that materially improves cost or speed, large commercial markets, measurable lives or emissions affected, proprietary data or workflow advantage, strong early evidence and a credible path to European and global scale.
No personal pass list is public. The published thesis implies weak fit for small or cosmetic impact, health claims without validation, AI without workflow or data advantage, products whose social benefit disappears as they scale, weak commercial returns and complex capital plans unsupported by milestone discipline.
Connect each commercial unit—trial, patient, site or workflow—to measurable time, cost and health outcomes as the company scales.
Require domain expertise, relevant data, workflow integration, validation and accountable human oversight rather than a generic model layer.
Show that the same product behavior that drives revenue also produces the claimed outcome, limiting mission drift and reporting ambiguity.
Match financing structure and milestone risk to the company's stage and avoid layered capital arrangements that hinder execution or future funding.
Impact and financial performance are converging, while large industrial transitions require patient conviction, simpler capital structures and transparent lessons from both wins and failures.
AI can create both major commercial savings and life-saving impact by improving clinical-trial protocol design, recruitment and execution and bringing treatments to patients faster.